Ep63: Jeremy Levin

Episode Summary

Executive Summary: Jeremy Levin argues biotech is in an existential political crisis despite unprecedented scientific progress. He says the industry must own past failures, reform pricing and compensation incentives, engage patients and policymakers, and build a social contract that preserves innovation while improving access, or risk losing public trust and investment.

Main Topics: Biotech’s political and reputational crisis (Priority: 5/5): Levin says pharma/biotech are viewed as profiteers and have become a political target, with public trust eroding and policymakers eager to act against the industry. Science is thriving, but the system is misaligned (Priority: 5/5): He contrasts the strongest-ever scientific era—cell therapy, gene therapy, and improved disease understanding—with pricing, access, and reimbursement systems that fail to translate innovation into patient benefit. Threats from government and private payers (Priority: 5/5): Levin warns about Medicare-for-All, international price indexing, and insurer/PBM consolidation, arguing each could suppress investment by crushing returns. The need for a new social contract (Priority: 5/5): He calls for each company to define a purpose centered on innovation and patient access, with boards and CEOs aligning incentives to sustainable long-term value rather than short-term profit. BIO’s role as convener and advocate (Priority: 4/5): Levin defines BIO’s mission as representing biotech’s innovation ecosystem in Washington, including health, ag, and environmental sectors, while focusing policy efforts on access and innovation rather than blame. Self-correction: pricing, biosimilars, and bad actors (Priority: 4/5): He acknowledges industry responsibility for unchecked price increases, perpetual biologics, weak biosimilar competition, and compensation systems that reward old-drug price hikes. U.S. strategic leadership in biotech (Priority: 4/5): Levin emphasizes the U.S. as the historical engine of biomedical innovation through NIH, venture capital, and capital markets, warning that China could gain advantage if the U.S. cripples its own ecosystem.

Key Arguments: Biotech is under unprecedented political attack because the public sees rising drug prices without understanding the value delivered by innovation. The industry cannot rely on Congress, payers, or trade groups alone; companies and CEOs must change behavior themselves. Medicare-for-All, international price indexing, and payer monopsony would all reduce returns and dry up investment in risky innovation. PBMs and intermediaries extract value without adding enough benefit, contributing to the disconnect between gross and net prices. Old-drug price inflation and perpetual biologic franchises have fueled public anger and made the case for reform harder. The industry should support access reforms, value-based contracts, and installment-style payments for transformative therapies. Boards should examine whether compensation systems reward patient value and innovation or short-term monetization of legacy products. BIO should focus on creating policy conditions for innovation and patient access across health, agriculture, and environmental biotech. A social contract is needed so companies clearly state their commitments to innovation, access, and societal responsibility. U.S. investment in NIH and basic science created the current innovation dividend, and preserving that leadership is a strategic national priority.

Data Points: BIO leadership tenure transition: Jim Greenwood retiring; Paul Hastings serving as vice chairman for seamless succession - Levin describes a new governance model to maintain continuity in BIO leadership Pipeline source from smaller companies: 70% - Levin says most pharmaceutical pipeline innovation originates in smaller biotech companies Social contract signatories initially: Over 200 - He says the letter calling for a social contract received over 200 signatures quickly Additional people asking to sign: Literally hundreds - Levin says many more companies/individuals later requested to sign or participate Old drug price increases: 9-10% every six months - He cites recurring price rises on ordinary medicines without added innovation Patent longevity: Permanent patents on many biologics; some still yielding billions after 20 years - Levin argues biosimilar competition has been too slow Conference timing: Recorded February 10 - He notes the interview was taped at the Bio CEO and Investor Conference in New York Historical origin of U.S. biotech ecosystem: 1947 - Levin points to NIH’s creation as the starting point for modern U.S. biomedical innovation Event promotion discount: $100 off with code 2020LOOK - Promotional mention for Life Science Innovation Northwest registration Subscription price: $1.49 a year - Promotional mention for Timmerman Report subscription

Pivotal Quotes: "best of times scientifically and the worst of times politically" — Jeremy Levin: His framing of the industry’s current moment "you stand on principle because nothing else matters" — Jeremy Levin: Levin links his personal history and leadership philosophy to biotech advocacy "our purpose, our raison. The reason that we exist is for two things: driving innovation and getting the patient the medicines that they need" — Jeremy Levin: He defines the social contract and BIO’s guiding principles

Implications: The industry faces a legitimacy test: reform pricing, incentives, and access or risk harsher regulation, weaker investment, and continued public backlash. Levin’s message is that sustainable biotech leadership requires visible self-correction now.